Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03824327 · ClinicalTrials.gov registry record · Phase 1

Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases

A Phase 1 study of Lung Non-Small Cell Carcinoma, sponsored by Ohio State University Comprehensive Cancer Center.

Active
Registry status
Phase 1
Development phase
19
Enrollment target
1
Study location

NCT03824327 is a Phase 1 study of Lung Non-Small Cell Carcinoma that is active but no longer recruiting, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 19 participants, below the 160-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03824327, a Phase 1 study of Lung Non-Small Cell Carcinoma, is active but no longer recruiting, sponsored by Ohio State University Comprehensive Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

This phase I trial studies the side effects and how well papaverine hydrochloride and stereotactic radiation therapy body (SBRT) work in treating patients with non-small cell lung cancer. Papaverine hydrochloride may help radiation therapy work better by making tumor cells more sensitive to the radiation therapy. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving papaverine hydrochloride with SBRT may work in treating patients with non-small cell lung cancer.

Conditions Studied

Lung Non-Small Cell Carcinoma

Interventions

  • RADIATION Stereotactic Body Radiation Therapy
  • PROCEDURE Blood Oxygen Level Dependent Imaging
  • DRUG Papaverine Hydrochloride

Study Locations (1)

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2019-02-07
Est. Completion 2027-12-31
Phase Phase 1

Sponsor

Ohio State University Comprehensive Cancer Center

341 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03824327

The ClinicalTrials.gov registry entry for NCT03824327 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 160-participant average among 47 other Lung Non-Small Cell Carcinoma trials with a reported enrollment target (88% lower). The listed sponsor is Ohio State University Comprehensive Cancer Center, which has 341 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Lung Non-Small Cell Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Stereotactic Body Radiation Therapy is the first listed.

NCT03824327 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.

Frequently Asked Questions

What is clinical trial NCT03824327 about?

NCT03824327 is a clinical study titled "Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases". This phase I trial studies the side effects and how well papaverine hydrochloride and stereotactic radiation therapy body (SBRT) work in treating patients with non-small cell lung cancer. Papaverine hydrochloride may help radiation therapy work better by making tumor cells more sensitive to the radi...

What is the current status of trial NCT03824327?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-02-07. Estimated completion is 2027-12-31.

What conditions does trial NCT03824327 study?

This clinical trial studies the following conditions: Lung Non-Small Cell Carcinoma.

What interventions are being tested in trial NCT03824327?

The interventions under investigation include: Stereotactic Body Radiation Therapy (RADIATION), Blood Oxygen Level Dependent Imaging (PROCEDURE), Papaverine Hydrochloride (DRUG).

Who is sponsoring clinical trial NCT03824327?

This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03824327 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Lung Non-Small Cell Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Lung Non-Small Cell Carcinoma

All registered trials for this condition

Ohio

All trials with a study site in Ohio

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.